The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age.

scientific article published on 14 January 2015

The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1179/1528433614Z.0000000006
P698PubMed publication ID25777188

P50authorJaime H VeraQ42237581
Borja Mora PerisQ84299648
Marta BoffitoQ95614617
P2093author name stringDavid Back
Tristan Barber
Alan Winston
Akil Jackson
Laura Dickinson
Laura Else
P2860cites workLife expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studiesQ24597052
HIV infection and older Americans: the public health perspectiveQ26858824
Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications.Q35608904
Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individualsQ36675900
Polypharmacy and risk of antiretroviral drug interactions among the aging HIV-infected populationQ37203653
Status of computerized cognitive testing in aging: a systematic review.Q37326855
HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidityQ37378238
Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitorQ37826300
The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patientsQ43102292
Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort StudyQ43867180
Effect of low-, moderate-, and high-fat meals on raltegravir pharmacokineticsQ44249118
Quantification of the HIV-integrase inhibitor raltegravir (MK-0518) in human plasma by high-performance liquid chromatography with fluorescence detectionQ44400672
Morbidity and aging in HIV-infected persons: the Swiss HIV cohort studyQ44518022
Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzymeQ45402590
HIV transmission and high rates of late diagnoses among adults aged 50 years and overQ45549222
Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects.Q51486190
Limited sampling strategies for the estimation of raltegravir daily exposure in HIV-infected patients.Q51595257
The assessment of cognitive function in advanced HIV-1 infection and AIDS dementia complex using a new computerised cognitive test battery.Q51986377
Practice effects associated with the repeated assessment of cognitive function using the CogState battery at 10-minute, one week and one month test-retest intervals.Q52012550
Antiretroviral therapy adherence and drug–drug interactions in the aging HIV populationQ57990925
P433issue1
P921main subjectpharmacokineticsQ323936
P304page(s)39-42
P577publication date2015-01-14
P1433published inHIV Clinical TrialsQ15756361
P1476titleThe pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age.
P478volume16

Reverse relations

cites work (P2860)
Q57180790British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015
Q40360498Plasma trough concentrations of darunavir/ritonavir and raltegravir in older patients with HIV-1 infection
Q47569821Precision medicine for HIV: where are we?

Search more.